跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2019-003805-82-FR
EUCTR2019-003805-82-FR进行中（未招募）1 期

CPVax plus Nivolumab versus standard chemotherapy as second line therapy in advanced non-small cell lung cancer : a randomized non-comparative phase II trial - Optim-UCPVax

CHU de Besançon0 个研究点目标入组 111 人开始时间: 2020年1月23日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
111
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1-Signed informed consent
  • •2-Male or female patients, age = 18 years
  • •3-Histologically or cytologically confirmed NSCLC (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, undifferentiated carcinoma or other)
  • •4-Advanced NSCLC cancer patient previously treated with a first line of combo chemotherapy plus anti-PD-1 or chemotherapy plus anti-PDL-1 combination
  • •5-Measurable disease defined according to RECIST v1.1 guidelines (Note: Previously irradiated lesions can be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.)
  • •6-Patients must have a mandatory treatment-free interval of at least 21 days following previous systemic anti-cancer treatments
  • •7-Patients who have received previous systemic anticancer treatment and/or radiotherapy should have recovered from any treatment related toxicity, to a level of = grade 1 (according to National Cancer Institute [NCI] common terminology criteria for adverse events, version 5 (CTCAE v5) with the exception of Grade 2 alopecia
  • •8-Performance status 0 or 1 on the ECOG scale
  • •9-Females must be using highly effective contraceptive measures and have a negative pregnancy test prior to the start of dosing if of childbearing potential, or must have evidence of non-childbearing potential by fulfilling one of the following criteria at screening:
  • •Post-menopausal is defined as aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments.
  • •Women under the age of 50 years would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution.
  • •Women with documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  • •Male patients with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 5 months following discontinuation of study drug. Patients should refrain from donating sperm from the start of dosing until 5 months after discontinuing study treatment.
  • •10-Affiliation to French social security or receiving such a regime.
  • •11-Ability to comply with the study protocol, in the Investigator’s judgment.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 74
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 37

排除标准

  • •1-Diagnosis of additional malignancy within 2 years prior to the inclusion with the exception of curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical or breast cancer
  • •2-Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study
  • •3-Participation in a clinical study with an investigational product within 4 weeks prior to the start of the study treatment
  • •4-Patient under guardianship, curatorship or under the protection of justice
  • •5-Uncontrolled pleural effusion, pericardial effusion, ascites or symptomatic fistula
  • •6-Uncontrolled tumor-related pain: Symptomatic lesions amenable to palliative radiotherapy should be treated prior to randomization. Patients should be recovered from the effects of radiation. There is no required minimum recovery period
  • •7-Known active central nervous system metastases and/or carcinomatous meningitis. Subject with previously treated brain metastases and with radiological and clinical stability are allowed.
  • •8-Presence of EGFR mutation, ALK or ROS1 translocation
  • •9-Uncontrolled brain metastases. Patients with controlled brain metastases after radiation therapy or with asymptomatic brain metastases may be included.
  • •10-Inadequate organ functions: known cardiac failure of unstable coronaropathy, respiratory failure, or uncontrolled infection or another life-risk condition
  • •11-Active or chronic hepatitis B or C and/or HIV positive (HIV 1/2 antibodies patients), or a known history of active Tuberculosis bacillus
  • •12-Any immunosuppressive therapy (i.e. corticosteroids >10mg of hydrocortisone or equivalent dose) within 14 days before the planned start of study therapy
  • •13-Active autoimmune disease that has required a systemic treatment in past 2 years (i.e. corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin) is allowed
  • •14-Active or history of autoimmune disease or immune deficiency,
  • •15-Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study,
  • •16-Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study,
  • •17-Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
  • •18-Prior allogeneic bone marrow transplantation or prior solid organ transplantation
  • •19-History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • •20-Known hypersensitivity or allergy to Chinese hamster ovary cell products or any component of Nivolumab formulation
  • •21-History of idiopathic or secondary pulmonary fibrosis (History of radiation pneumonitis in the radiation field fibrosis is permitted), or evidence of active pneumonitis requiring a systemic treatment with 28 days before the planned start of study therapy
  • •22-Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
  • •23-Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
  • •24-Treatment with therapeutic oral

研究者

相似试验

招募中
2 期
Use of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and dexamethasone (BGD) with autologous bone marrow transplantation in patients with Hodgkin’s lymphoma refractory to 1-line therapy.
2024-515064-31-00Medical University Of Gdansk84
招募中
2 期
Phase II study of chemotherapy plus nivolumab followed by conversion surgery for Stage IV gastric cancer with a single non-curable factor
JPRN-jRCTs051220065Kurokawa Yukinori70
进行中（未招募）
1 期
Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 StudyAcute Myeloid LeukaemiaMedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2020-000273-24-GBniversity of Birmingham186
已完成
不适用
Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms
PER-015-08EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
进行中（未招募）
1 期
Immunotherapy in combination with chemotherapy in small-cell lung cancer.
EUCTR2017-004784-12-GRHellenic Cooperative Oncology Group (HeCOG)55